4/A: Vera Therapeutics CEO Sells Shares
Insider Transaction (Form 4/A)
Marshall Fordyce, PRESIDENT AND CEO and a Director of Vera Therapeutics, Inc., sold 46,250 shares of common stock on July 7, 2026.
Summary
- Option exercise/conversion: acquired 46,250 Class A Common Stock at $2.90 ($133,977) on July 7, 2026; holds 281,494 after (Direct).
- Open-market sale: disposed of 1,000 Class A Common Stock at $40.78 ($40,776) on July 7, 2026; holds 280,494 after (Direct).
- Open-market sale: disposed of 32,550 Class A Common Stock at $42.07 ($1,369,496) on July 7, 2026; holds 247,944 after (Direct).
- Open-market sale: disposed of 10,500 Class A Common Stock at $42.86 ($450,007) on July 7, 2026; holds 237,444 after (Direct).
- Open-market sale: disposed of 2,200 Class A Common Stock at $43.59 ($95,908) on July 7, 2026; holds 235,244 after (Direct).
- Option exercise/conversion: disposed of 46,250 Stock Option (Right to Buy) on July 7, 2026; holds 525,801 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $1,956,187 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Marshall Fordyce — Director, Officer (PRESIDENT AND CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-07 | Option exercise/conversion | Class A Common Stock | 46,250 | $3 | $134.0K | 281,494 |
| 2026-07-07 | Open-market sale | Class A Common Stock | 1,000 | $41 | $40.8K | 280,494 |
| 2026-07-07 | Open-market sale | Class A Common Stock | 32,550 | $42 | $1.4M | 247,944 |
| 2026-07-07 | Open-market sale | Class A Common Stock | 10,500 | $43 | $450.0K | 237,444 |
| 2026-07-07 | Open-market sale | Class A Common Stock | 2,200 | $44 | $95.9K | 235,244 |
| 2026-07-07 | Option exercise/conversion | Stock Option (Right to Buy) | 46,250 | — | — | 525,801 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-07 | Option exercise/conversion (46,250 shares) |
| 2026-07-07 | Open-market sale (1,000 shares) |
| 2026-07-07 | Open-market sale (32,550 shares) |
| 2026-07-07 | Open-market sale (10,500 shares) |
| 2026-07-07 | Open-market sale (2,200 shares) |
| 2026-07-07 | Option exercise/conversion (46,250 shares) |
Keywords
insider transaction, Form 4/A, VERA, Vera Therapeutics, Inc., bearish, Marshall Fordyce
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.